Evolus’ (EOLS) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Evolus (NASDAQ:EOLS) in a research note published on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $22.00 target price on the stock.

Several other research analysts have also recently commented on the stock. Barclays raised their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Evolus in a report on Wednesday.

Evolus Trading Up 0.6 %

Shares of EOLS stock opened at $13.58 on Wednesday. Evolus has a 12-month low of $9.25 and a 12-month high of $17.82. The firm has a 50 day moving average price of $12.90 and a two-hundred day moving average price of $14.08. The company has a market capitalization of $859.90 million, a PE ratio of -14.92 and a beta of 1.33. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Evolus by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company’s stock valued at $347,000 after acquiring an additional 1,094 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Evolus by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock worth $148,000 after buying an additional 1,291 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Evolus by 2.2% during the fourth quarter. Rhumbline Advisers now owns 80,149 shares of the company’s stock worth $885,000 after buying an additional 1,762 shares in the last quarter. Tradition Wealth Management LLC increased its holdings in shares of Evolus by 18.2% during the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company’s stock worth $144,000 after buying an additional 2,000 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in shares of Evolus by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 34,272 shares of the company’s stock worth $378,000 after buying an additional 2,044 shares in the last quarter. 90.69% of the stock is owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.